Femara

[InfoI]

<h1>Femara </h1><p>Femara (letrozole tablets) was approved for use in the United States in 1997 and has been helping postmenopausal women with hormone receptor-positive early breast cancer ever since. Throughout its history, Femara has demonstrated effectiveness in treating various stages of this condition from early to locally advanced to metastatic. In postmenopausal women with hormone receptor-positive early stage breast cancer, in the adjuvant setting, Femara has been shown to help reduce the risk of breast cancer returning versus tamoxifen. Based on 26 months of follow-up data, Femara significantly reduces the risk of distant metastasis when it is taken as initial adjuvant therapy after surgery. Femara also has been shown to reduce the risk of breast cancer returning when taken within three months of completion of five years of tamoxifen therapy. In addition, Femara reduced the risk of disease progression in patients with advanced breast cancer. Further follow-up will be needed to determine long-term results, including safety and efficacy. Femara has not been shown to improve survival versus tamoxifen. Time to distant metastasis and overall survival are secondary end points, and the primary end point of this study is DFS (disease-free survival). Approval in the adjuvant setting was based on a median of 26 months of follow-up.</p>